Table 1.
Patient, disease and transplant characteristics
| Characteristics of patients | Autologous, N (%) | Allogeneic, N (%) | P-value |
|---|---|---|---|
| Number of patients | 90 | 92 | |
| Age at transplant, years | |||
| ≤ 10 | 26 (29) | 29 (32) | |
| 11 – 18 | 64 (71) | 63 (68) | |
| Performance score prior to TX | 0.12 | ||
| < 90% | 17 (19) | 29 (32) | |
| ≥ 90% | 70 (78) | 60 (65) | |
| Unknown | 3 ( 3) | 3 ( 3) | |
| Disease | <0.001 | ||
| Diffuse large cell | 35 (38) | 17 (19) | |
| Lymphoblastic | 14 (16) | 39 (42) | |
| Burkitt | 17 (19) | 24 (26) | |
| Anaplastic | 24 (27) | 12 (13) | |
| Interval diagnosis to transplant | 0.54 | ||
| < 6 months | 9 (10) | 5 ( 5) | |
| 6 – 12 months | 30 (33) | 33 (36) | |
| ≥ 12 months | 51 (57) | 54 (59) | |
| Disease status prior to transplant | 0.65 | ||
| ≥ second complete remission | 43 (48) | 47 (51) | |
| Relapse or Progression | 47 (52) | 45 (49) | |
| Interval from diagnosis to 1st relapse1 | 0.18 | ||
| < 6 months | 15(20) | 29 (32) | |
| 6 – 12 months | 23 (30) | 21 (23) | |
| > 12 months | 38 (50) | 40 (44) | |
| Conditioning regimen | <0.001 | ||
| Total body irradiation + cyclophosphamide | 25 (28) | 74 (80) | |
| Total body irradiation + other agents | 10 (11) | 5 ( 6) | |
| Busulfan + cyclophosphamide | 4 ( 5) | 13 ( 2) | |
| Cyclophosphamide + etoposide | 26 (29) | 0 | |
| Other | 25 (27) | 0 | |
| Graft type | <0.001 | ||
| Bone marrow | 39 (43) | 75 (82) | |
| Peripheral blood | 51 (57) | 17 (18) | |
| Year of transplant | < 0.001 | ||
| 1990–1994 | 47 (52) | 12 (13) | |
| 1995–2005 | 43 (48) | 80 (87) | |
| Type of Donor | |||
| HLA-identical sibling | NA | 43 (47) | |
| Unrelated 2 | 49 (53) | ||
| Median (range) follow-up, months |
71 (2 – 142) | 43 (2 – 157) | |
1
Excludes patients who did not achieve first CR; n = 2 allogeneic transplant recipients and n = 14 autologous transplant recipients had progressive disease with front-line therapy and proceeded to transplantation without achieving CR
2
Matched URD, n=9; Mismatched URD, n= 40